

Media Outlet: Process Worldwide

Date: 10th September

URL: <http://www.process-worldwide.com/pharma-and-food/articles/503910/index2.html>

The screenshot shows the Process Worldwide website interface. At the top, there is a search bar and a navigation menu with categories like NEWS, VIDEOS, WHITEPAPER, COMPANIES, EVENTS, DIGITAL ISSUE, ACHEMA, and ADD NEWS. Below the navigation, there is a breadcrumb trail: "You are here: Topics > Pharma & Food". The main article title is "M&A in Pharmaceuticals" followed by "India's Pharmaceutical Industry on the Move: M&A Increases by 44.5%". The article is dated 09/10/2015 and edited by Dominik Stephan. There are social media sharing icons for X, Facebook, Twitter, LinkedIn, and Google+. Below the article, there is a call to action: "Never miss out on any PROCESS-WORLDWIDE.com news again! Become a registered user now." with a "Subscribe now, for free!" button. To the right of the article, there is a "RELATED TOPICS" section with four featured articles: "Potentials on India's Biotechnology Market", "Emphasis on Energy Efficiency Boosts", "India Rides on a Growth Curve", and "Lupin Inks Strategic Joint Venture". At the bottom of the page, there is an advertisement placeholder.

India accounts for 30.3 % (2,911) of 9619 Drug Master Files (DMFs) filed with the USA, which is the highest outside of the USA. India has been accredited with approximately 1187 CEPs, more than 950TGA, and 584 sites approved by USFDA. Despite a challenging intellectual property regime, pharmaceutical R&D activities are increasing in India. An average of 8-10% of the total revenue of the India domestic pharma market, i.e. US \$ 15 billion, is spent on R&D.

Zyudus Cadilla has launched "Lipaglyn" (Chemical name is Sarogltazar), its original research being to treat Hypertriglycerdemia in Type-2 diabetes. Glenmark has several new chemical and biologics. Contract Research and Manufacturing Services (CRAMS) in India is estimated to reach US\$ 18 billion in 2018, up from US \$ 7.6–7.8 billion in 2013. The biopharma market is valued at US \$ 2.5 billion whereas India is expected to grab at least 20-25% of global market share in biosimilars in the next five years.

Cooperations with Japanese Companies

India is also making inroads to new regulated markets like Japan. Several initiatives have been undertaken by industry for engaging with Japanese pharma companies, including contract manufacturing of advance intermediates for drugs under clinical development/about to be made commercial, marketing APIs to Japanese Generic and Innovation companies, providing quality intermediates to the Japanese innovator companies.

In summary, the last few years have reshaped and repositioned India in the realm of healthcare and pharmaceuticals, and the results have started to show in its high ranking position in the global pharmaceutical market.